当前位置： SCI文献检索 > JOURNAL OF HEPATOLOGY期刊下所有文献 > Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.

Abstract：

BACKGROUND & AIMS:Sorafenib is associated with multiple adverse events (AEs), potentially causing its permanent interruption. It is unknown how physicians' experience has impacted on the management of these AEs and consequently on clinical outcomes. We aimed to assess whether AE management changed over time and if these modifications impacted on treatment duration and overall survival (OS). METHODS:We analysed the prospectively collected data of 338 consecutive patients who started sorafenib between January 2008 and December 2017 in 3 tertiary care centres in Italy. Patients were divided according to the starting date: Group A (2008-2012; n = 154), and Group B (2013-2017, n = 184). Baseline and follow-up data were compared. In the OS analysis, patients who received second-line treatments were censored when starting the new therapy. RESULTS:Baseline characteristics, AEs, and radiological response were consistent across groups. Patients in Group B received a lower median daily dose (425 vs. 568 mg/day, p <0.001) due to more frequent dose modifications. However, treatment duration was longer (5.8 vs. 4.1 months, p = 0.021) with a trend toward a higher cumulative dose in Group B. Notably, the OS was also higher (12.0 vs. 11.0 months, p = 0.003) with a sharp increase in the 2-year survival rate (28.1 vs. 18.4%, p = 0.003) in Group B. Multivariate time-dependent Cox regression analysis confirmed later period of treatment (2013-2017) as an independent predictor of survival (HR 0.728; 95%CI 0.581-0.937; p = 0.013). Unconsidered confounders were unlikely to affect these results at the sensitivity analysis. CONCLUSIONS:Experience in the management of sorafenib-related AEs prolongs treatment duration and survival. This factor should be considered in the design of future randomised clinical trials including a sorafenib treatment arm, as an underestimate of sample size may derive. LAY SUMMARY:Sorafenib has been the standard frontline systemic treatment for hepatocellular carcinoma for over a decade. Its tolerability is limited by different adverse events, which might lead to its permanent discontinuation in a sizeable proportion of patients. After a careful analysis of potential confounders, we demonstrated that the physicians' experience in managing adverse events related to sorafenib has improved over time, with longer treatment periods and less permanent discontinuation for toxicities. More importantly, these improvements also translated into longer patient survival. Our results have relevant repercussions in clinical practice and in the design of future clinical trials.

journal_name

J Hepatol

journal_title

Journal of hepatology

authors

Tovoli F,Ielasi L,Casadei-Gardini A,Granito A,Foschi FG,Rovesti G,Negrini G,Orsi G,Renzulli M,Piscaglia F

doi

10.1016/j.jhep.2019.08.015

subject

Has Abstract

pub_date

2019-12-01 00:00:00

pages

1175-1183

issue

eissn

0168-8278

issn

1600-0641

pii

S0168-8278(19)30482-9

journal_volume

pub_type

杂志文章

在线工具

Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.